LT3077395T - Pirolo[2,3-d]pirimidinilo, pirolo[2,3-b]pirazinilo ir pirolo[2,3-d]piridinilo akrilamidai - Google Patents

Pirolo[2,3-d]pirimidinilo, pirolo[2,3-b]pirazinilo ir pirolo[2,3-d]piridinilo akrilamidai

Info

Publication number: LT3077395T
Authority: LT; Lithuania
Prior art keywords: pyrrolo; pyrazinyl; pyrimidinyl; acrylamides; pyridinyl
Prior art date: 2013-12-05

Application number

LTEP14816404.9T

Other languages

English (en)

Inventor

Matthew Frank Brown

Agustin Casimiro-Garcia

Ye Che

Jotham Wadsworth Coe

Mark Edward Flanagan

Adam Matthew Gilbert

Matthew Merrill Hayward

Jonathan David LANGILLE

Justin Ian Montgomery

Jean-Baptiste Telliez

Atli Thorarensen

Rayomand Jal Unwalla

John I Trujillo

Original Assignee

Pfizer Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-12-05

Filing date

2014-11-20

Publication date

2018-02-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52144776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3077395(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-11-20 Application filed by Pfizer Inc. filed Critical Pfizer Inc.

2018-02-12 Publication of LT3077395T publication Critical patent/LT3077395T/lt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Immunology (AREA)
Hematology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychiatry (AREA)
Psychology (AREA)
Reproductive Health (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)

LTEP14816404.9T 2013-12-05 2014-11-20 Pirolo[2,3-d]pirimidinilo, pirolo[2,3-b]pirazinilo ir pirolo[2,3-d]piridinilo akrilamidai LT3077395T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361912074P	2013-12-05	2013-12-05
PCT/IB2014/066202 WO2015083028A1 (en)	2013-12-05	2014-11-20	Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides

Publications (1)

Publication Number	Publication Date
LT3077395T true LT3077395T (lt)	2018-02-12

Family

ID=52144776

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
LTEP14816404.9T LT3077395T (lt)	2013-12-05	2014-11-20	Pirolo[2,3-d]pirimidinilo, pirolo[2,3-b]pirazinilo ir pirolo[2,3-d]piridinilo akrilamidai
LTEP17200940.9T LT3318565T (lt)	2013-12-05	2014-11-20	Pirolo[2,3-d]pirimidinilo, pirolo[2,3-b]pirazinilo ir pirolo[2,3-d]piridinilo akrilamidai
LTPA2023537C LTC3077395I2 (lt)	2013-12-05	2023-12-13

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
LTEP17200940.9T LT3318565T (lt)	2013-12-05	2014-11-20	Pirolo[2,3-d]pirimidinilo, pirolo[2,3-b]pirazinilo ir pirolo[2,3-d]piridinilo akrilamidai
LTPA2023537C LTC3077395I2 (lt)	2013-12-05	2023-12-13

Country Status (48)

Country	Link
US (4)	US9617258B2 (lt)
EP (2)	EP3077395B1 (lt)
JP (2)	JP6192839B2 (lt)
KR (1)	KR101930603B1 (lt)
CN (2)	CN106061973B (lt)
AP (1)	AP2016009269A0 (lt)
AR (1)	AR099363A1 (lt)
AU (1)	AU2014358792C1 (lt)
BR (1)	BR112016012262B1 (lt)
CA (1)	CA2932425C (lt)
CL (1)	CL2016001216A1 (lt)
CR (1)	CR20160250A (lt)
CU (1)	CU24396B1 (lt)
CY (3)	CY1119778T1 (lt)
DK (2)	DK3077395T3 (lt)
DO (1)	DOP2016000124A (lt)
EA (1)	EA030472B1 (lt)
ES (2)	ES2871524T3 (lt)
FI (1)	FIC20230035I1 (lt)
FR (1)	FR23C1042I2 (lt)
GE (1)	GEP20186840B (lt)
GT (1)	GT201600098A (lt)
HR (2)	HRP20171846T1 (lt)
HU (3)	HUE054560T2 (lt)
IL (1)	IL246038B (lt)
LT (3)	LT3077395T (lt)
LU (1)	LUC00322I2 (lt)
MA (1)	MA39092B1 (lt)
MD (1)	MD4649C1 (lt)
ME (1)	ME02883B (lt)
MX (1)	MX368464B (lt)
MY (1)	MY187446A (lt)
NI (1)	NI201600075A (lt)
NL (1)	NL301245I2 (lt)
NO (2)	NO3134430T3 (lt)
NZ (1)	NZ720092A (lt)
PE (1)	PE20161246A1 (lt)
PH (1)	PH12016500938B1 (lt)
PL (2)	PL3077395T3 (lt)
PT (2)	PT3077395T (lt)
RS (2)	RS61897B9 (lt)
SI (2)	SI3318565T1 (lt)
SV (1)	SV2016005209A (lt)
TN (1)	TN2016000227A1 (lt)
TW (1)	TWI548636B (lt)
UA (1)	UA117040C2 (lt)
UY (1)	UY35861A (lt)
WO (1)	WO2015083028A1 (lt)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX368781B (es) *	2013-09-18	2019-10-16	Beijing Hanmi Pharmaceutical Co Ltd	Compuesto inhibidor de las actividades de las cinasas btk y/o jak3.
PE20161246A1 (es) *	2013-12-05	2016-11-25	Pfizer	Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinilo
CN105777756B (zh) *	2014-07-02	2019-03-01	广东东阳光药业有限公司	杂芳化合物及其在药物中的应用
KR102043337B1 (ko)	2014-08-28	2019-11-11	아셰뉴론 에스아	글리코시다제 저해제
CN105712998B (zh) *	2014-12-05	2019-12-13	上海润诺生物科技有限公司	氮杂吲哚类衍生物、其制备方法及其在医药上的应用
AU2016209046A1 (en) *	2015-01-23	2017-07-20	Aclaris Therapeutics, Inc.	Heterocyclic ITK inhibitors for treating inflammation and cancer
CN105837574B (zh) *	2015-02-02	2018-03-02	四川大学	N‑(3‑哌啶基)‑芳香胺衍生物及其制备方法和用途
EP3288943B1 (en) *	2015-05-01	2022-09-28	Pfizer Inc.	Pyrrolo[2,3-b]pyrazinyl acrylamides and epoxides thereof as inhibitors of janus kinase
KR102081272B1 (ko) *	2015-05-29	2020-02-25	우시 포춘 파마슈티컬 컴퍼니 리미티드	Janus 키나아제 억제제
CN106432246B (zh) *	2015-08-05	2020-07-07	广东东阳光药业有限公司	杂芳化合物及其在药物中的应用
KR101771219B1 (ko) *	2015-08-21	2017-09-05	양지화학 주식회사	야누스 키나제 1 선택적 억제제 및 그 의약 용도
CN108349972B (zh)	2015-11-03	2021-06-08	施万生物制药研发Ip有限责任公司	用于治疗呼吸疾病的jak激酶抑制剂化合物
US9630968B1 (en)	2015-12-23	2017-04-25	Arqule, Inc.	Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
CN109071526B (zh)	2016-02-25	2023-02-28	阿森纽荣股份公司	哌嗪衍生物的酸加成盐
US11261183B2 (en)	2016-02-25	2022-03-01	Asceneuron Sa	Sulfoximine glycosidase inhibitors
US11612599B2 (en)	2016-02-25	2023-03-28	Asceneuron Sa	Glycosidase inhibitors
US10556902B2 (en)	2016-02-25	2020-02-11	Asceneuron Sa	Glycosidase inhibitors
BR112018074621B1 (pt)	2016-06-30	2021-06-08	Daewoong Pharmaceutical Co., Ltd	compostos derivados de pirazolopirimidina como inibidores de quinase, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
TW201811795A (zh)	2016-08-24	2018-04-01	美商亞闊股份有限公司	胺基－吡咯并嘧啶酮化合物及其用途
TWI771342B (zh) *	2016-11-23	2022-07-21	大陸商江蘇恆瑞醫藥股份有限公司	吡咯并六員雜芳環類衍生物的製備方法及中間體
PT3511333T (pt) *	2016-11-23	2021-08-02	Wuxi Fortune Pharmaceutical Co Ltd	Forma cristalina e forma de sal do composto 7hpirrolo[ 2,3-d]pirimidina e método de preparação para o mesmo
CN110291090A (zh) *	2017-01-20	2019-09-27	利奥制药有限公司	作为新型jak激酶抑制剂的双环胺
JP2020509004A (ja)	2017-02-27	2020-03-26	ヤンセンファーマシューティカエヌ．ベー．	Ｏｇａ阻害剤としての、ピペリジン、モルホリンまたはピペラジンで置換されている［１，２，４］−トリアゾロ［１，５−ａ］−ピリミジニル誘導体
US10196393B2 (en)	2017-03-09	2019-02-05	Theravance Biopharma R&D Ip, Llc	JAK inhibitors containing a 4-membered heterocyclic amide
CN108794480A (zh) *	2017-04-28	2018-11-13	天津药物研究院有限公司	吡咯并嘧啶类化合物、其制备方法和用途
WO2018204233A1 (en)	2017-05-01	2018-11-08	Theravance Biopharma R&D Ip, Llc	Methods of treatment using a jak inhibitor compound
WO2018204236A1 (en)	2017-05-01	2018-11-08	Theravance Biopharma R&D Ip, Llc	Crystalline forms of a jak inhibitor compound
AR111495A1 (es)	2017-05-01	2019-07-17	Theravance Biopharma R&D Ip Llc	Compuestos de imidazo-piperidina fusionada como inhibidores de jak
WO2019027960A1 (en)	2017-08-01	2019-02-07	Theravance Biopharma R&D Ip, Llc	BICYCLIC PYRAZOLO AND TRIAZOLO COMPOUNDS AS JAK KINASE INHIBITORS
WO2019037860A1 (en)	2017-08-24	2019-02-28	Asceneuron S.A.	LINEAR INHIBITORS OF GLYCOSIDASE
CN111566095B (zh)	2017-11-03	2024-09-27	阿克拉瑞斯治疗股份有限公司	被取代的吡咯并吡啶jak抑制剂及其制造方法和使用方法
MX2020004566A (es) *	2017-11-07	2020-08-13	Univ Michigan Regents	Inhibidores de molécula pequeña de interacciones de epítopo compartido-calreticulina y métodos de uso.
CN107857778B (zh) *	2017-11-21	2020-03-24	江苏乐斯化学有限公司	含膦酰基的α-氨基腈的制备方法
KR102577242B1 (ko) *	2017-12-28	2023-09-11	주식회사 대웅제약	카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
PE20201146A1 (es) *	2017-12-28	2020-10-26	Dae Woong Pharma	Derivado de oxi-fluoropiperidina como inhibidor de quinasa
KR102577241B1 (ko) *	2017-12-28	2023-09-11	주식회사 대웅제약	카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
JP7462951B2 (ja) *	2018-03-21	2024-04-08	リャオ，シビン	Ｊａｋ阻害剤
CN108358797A (zh) *	2018-04-20	2018-08-03	南京农业大学	一种烷基甘氨酸的合成方法
CN108640923A (zh) *	2018-07-09	2018-10-12	湖南天地恒制药有限公司	一种托法替布关键中间体的制备方法
CA3107548A1 (en) *	2018-08-06	2020-02-13	Moexa Pharmaceuticals Limited	Smad3 inhibitors
CN112823005B (zh) *	2018-08-10	2024-08-20	阿克拉瑞斯治疗股份有限公司	吡咯并嘧啶itk抑制剂
US11795165B2 (en)	2018-08-22	2023-10-24	Asceneuron Sa	Tetrahydro-benzoazepine glycosidase inhibitors
WO2020039029A1 (en)	2018-08-22	2020-02-27	Asceneuron S. A.	Spiro compounds as glycosidase inhibitors
US12016852B2 (en)	2018-08-22	2024-06-25	Asceneuron Sa	Pyrrolidine glycosidase inhibitors
MX2021002111A (es)	2018-08-22	2021-07-16	Asceneuron S A	Sales de adición de ácido de succinato y fumarato de derivados de piperazina útiles como inhibidores de glucosidasa.
BR112021004052A2 (pt)	2018-09-04	2021-05-25	Theravance Biopharma R&D Ip, Llc	amidas de dimetil-amino azetidina como inibidores de jak
CN112638902A (zh)	2018-09-04	2021-04-09	施万生物制药研发Ip有限责任公司	用于制备jak抑制剂的方法及其中间体
MX2021002484A (es)	2018-09-04	2021-05-12	Theravance Biopharma R&D Ip Llc	Amidas heterociclicas de 5 a 7 miembros como inhibidores de jak.
WO2020067887A1 (en)	2018-09-24	2020-04-02	Erasmus University Medical Center Rotterdam	Specific inhibition of janus kinase 3 (jak3) for modulating anti-tumor immune responses
JP6944496B2 (ja) *	2018-10-22	2021-10-06	ファイザー・インク	ピロロ［２，３−ｄ］ピリミジントシル酸塩、その結晶形態、ならびにその製造方法および中間体
US10968222B2 (en)	2018-10-29	2021-04-06	Theravance Biopharma R&D Ip, Llc	2-azabicyclo hexane JAK inhibitor compound
WO2020154350A1 (en)	2019-01-23	2020-07-30	Theravance Biopharma R&D Ip, Llc	Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors
EP3939979A4 (en) *	2019-03-14	2022-04-06	Shanghai Synergy Pharmaceutical Sciences Co., Ltd	Jak kinase inhibitor, preparation method for same, and applications thereof in field of medicine
WO2020198583A1 (en)	2019-03-27	2020-10-01	Insilico Medicine Ip Limited	Bicyclic jak inhibitors and uses thereof
WO2020223728A1 (en) *	2019-05-02	2020-11-05	Aclaris Therapeutics, Inc.	Substituted pyrrolopyridines as jak inhibitors
EP3969458A4 (en)	2019-05-13	2023-05-17	Borah, Inc.	CHEMICAL COMPOUNDS
JOP20210298A1 (ar)	2019-05-14	2023-01-30	Provention Bio Inc	طرق وتركيبات للوقاية من مرض السكري من النوع الأول
CN110183455B (zh) *	2019-06-18	2021-04-20	中国医科大学	氮杂双环[3.2.1]辛-3-酮类化合物及其制备方法与其用途
CN112430235B (zh) *	2019-08-26	2024-04-05	东莞市东阳光仿制药研发有限公司	一种pf-06651600中间体的制备方法
CN114761013A (zh)	2019-09-27	2022-07-15	迪斯克医药公司	治疗骨髓纤维化和相关病症的方法
KR102228668B1 (ko)	2019-10-08	2021-03-17	(주)부흥산업사	메틸피퍼리딘 아미노피롤로 피리미딘의 제조방법
CA3161153A1 (en)	2019-11-14	2021-05-20	Pfizer Inc.	1-(((2s,3s,4s)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide combinations and oral dosage forms
CN112824381B (zh) *	2019-11-21	2024-04-26	广东东阳光药业股份有限公司	一种哌啶胺的制备方法
CN113121413B (zh) *	2019-12-31	2024-04-09	江苏艾立康医药科技有限公司	一种jak3酶抑制剂关键中间体的制备方法
US20230338380A1 (en) *	2019-12-31	2023-10-26	Pfizer R&D Uk Limited	Stable Immediate Release Tablet and Capsule Formulations of 1-((2S,5R)-5-((7H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino)-2-Methylpiperidin-1-YL)Prop-2-EN-1-One
CN113121539A (zh) *	2019-12-31	2021-07-16	江苏艾立康医药科技有限公司	一种pf06651600的制备方法
CN111138361B (zh) *	2020-01-03	2022-05-06	中国医科大学	取代苯氧基-2-氮杂双环[3.2.1]辛烷类化合物及其制备方法和应用
WO2021147953A1 (zh) *	2020-01-21	2021-07-29	江苏先声药业有限公司	嘧啶并五元环类衍生物及其应用
EP4100409B1 (en) *	2020-02-03	2024-08-28	Boehringer Ingelheim International GmbH	[1,3]diazino[5,4-d]pyrimidines as her2 inhibitors
TW202144343A (zh)	2020-03-02	2021-12-01	美商施萬生物製藥研發 Ip有限責任公司	Jak抑制劑化合物之結晶水合物
US20230149407A1 (en)	2020-04-04	2023-05-18	Pfizer Inc.	Methods of Treating Coronavirus Disease 2019
KR20230012539A (ko)	2020-05-13	2023-01-26	디스크 메디슨, 인크.	골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
WO2021252917A2 (en)	2020-06-11	2021-12-16	Provention Bio, Inc.	Methods and compositions for preventing type 1 diabetes
CN111620880B (zh) *	2020-06-15	2022-06-10	江苏艾立康医药科技有限公司	Pf-06651600 dl-酒石酸盐，晶型及其制备方法
CN111620879B (zh) *	2020-06-15	2022-06-10	江苏艾立康医药科技有限公司	Pf-06651600马来酸盐，晶型及其制备方法
WO2022002210A1 (zh) *	2020-07-02	2022-01-06	南京明德新药研发有限公司	嘧啶并吡咯基类氘代化合物
WO2022012587A1 (zh) *	2020-07-14	2022-01-20	苏州晶云药物科技股份有限公司	丙烯酮类化合物的丙二酸盐晶型及其制备方法
CN111995623A (zh) *	2020-08-18	2020-11-27	上海毕得医药科技有限公司	一种7-溴-4-氯-1-甲基-1H-咪唑并[4,5-c]吡啶的合成方法
KR102473645B1 (ko)	2020-08-28	2022-12-05	(주)부흥산업사	(2S,5R)-벤질 5-(t-부톡시카르보닐아미노)-2-메틸피페리딘-1-카르복실레이트의 제조방법
CN113061137B (zh) *	2021-04-02	2022-08-02	广西医科大学	含氮杂环衍生物或其药学上可接受的盐和用途
JP2024524214A (ja)	2021-06-25	2024-07-05	セラヴァンスバイオファーマアール＆ディーアイピー，エルエルシー	Ｊａｋ阻害剤としてのイミダゾロインダゾール化合物
CN113429427A (zh) *	2021-07-05	2021-09-24	湖南南新制药股份有限公司	杂环化合物及其制备方法和药物用途
CN115724857B (zh) *	2021-08-25	2024-06-21	杭州禹泓医药科技有限公司	一种芳杂环类化合物、含其的药物组合物及其应用
WO2023029943A1 (zh) *	2021-09-03	2023-03-09	星药科技(北京)有限公司	一种芳杂环化合物及其制备方法和用途
WO2023151069A1 (zh) *	2022-02-14	2023-08-17	湖南南新制药股份有限公司	吡咯并[2,3-d]六元杂芳环衍生物、其制备方法和药物用途
WO2024084363A1 (en)	2022-10-18	2024-04-25	Pfizer Inc.	Use of patatin-like phospholipase domain-containing protein 3 compounds
EP4605076A1 (en)	2022-10-18	2025-08-27	Pfizer Inc.	Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers
WO2024150110A1 (en)	2023-01-11	2024-07-18	Pfizer Inc.	Compositions and methods for the treatment and/or prevention of type 1 diabetes
CN116120347B (zh) *	2023-01-18	2024-08-23	杭州禹泓医药科技有限公司	芳杂环类化合物的晶型、其组合物、制备方法及其应用
CN116496280B (zh) *	2023-06-25	2023-09-08	北京科翔中升医药科技有限公司	氘代丙烯酰胺类jak3抑制剂药物及用途
WO2025146702A1 (en) *	2024-01-03	2025-07-10	Msn Laboratories Private Limited, R&D Center	Solid state forms of 1-{(2s,5r)-2-methyl-5-[(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino] piperidine-1-yl}prop-2-en-1-one 4-methylbenzene-1-sulfonic acid
WO2025181247A1 (en) *	2024-02-28	2025-09-04	Almirall, S.A.	Heterobicyclic derivatives as itk inhibitors
WO2025257773A1 (en)	2024-06-11	2025-12-18	Assia Chemical Industries Ltd.	Processes for the preparation of ritlecitinib and intermediates thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PA8474101A1 (es)	1998-06-19	2000-09-29	Pfizer Prod Inc	Compuestos de pirrolo [2,3-d] pirimidina
AU3951899A (en)	1998-06-19	2000-01-05	Pfizer Products Inc.	Pyrrolo(2,3-d)pyrimidine compounds
DE60037345T2 (de)	1999-12-10	2008-11-13	Pfizer Products Inc., Groton	Pyrrolo(2,3-d)pyrimidin-Verbindungen
AU784297C (en) *	2000-06-26	2007-01-11	Pfizer Products Inc.	Pyrrolo(2,3-d)pyrimidine compounds as immunosuppressive agents
US7301023B2 (en)	2001-05-31	2007-11-27	Pfizer Inc.	Chiral salt resolution
CN101353321A (zh)	2002-11-21	2009-01-28	辉瑞产品公司	3-氨基-哌啶衍生物及其制备方法
AR054416A1 (es)	2004-12-22	2007-06-27	Incyte Corp	Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
EP2251341A1 (en)	2005-07-14	2010-11-17	Astellas Pharma Inc.	Heterocyclic Janus kinase 3 inhibitors
NZ565363A (en)	2005-07-29	2010-03-26	Pfizer Prod Inc	Pyrrolo[2,3-D]pyrimidine derivatives; their intermediates and synthesis
WO2007062459A1 (en)	2005-11-29	2007-06-07	Cytopia Research Pty Ltd	Selective kinase inhibitors based on pyridine scaffold
HUE025173T2 (hu)	2005-12-13	2016-01-28	Incyte Corp	Heteroaril-szubsztituált pirrollo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
EP2526934B1 (en)	2006-09-22	2015-12-09	Pharmacyclics LLC	Inhibitors of bruton's tyrosine kinase
JO3041B1 (ar)	2008-07-25	2016-09-05	Galapagos Nv	مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
ES2378513T3 (es)	2008-08-06	2012-04-13	Pfizer Inc.	Compuestos 2-heterociclilamino piracinas sustituidas en posiciÃ³n 6 como inhibidores de CHK-1
WO2010028236A1 (en)	2008-09-05	2010-03-11	Avila Therapeutics, Inc.	Algorithm for designing irreversible inhibitors
RU2539568C2 (ru)	2008-10-31	2015-01-20	Дженентек, Инк.	Пиразолопиримидиновые соединения-ингибиторы jak и способы
JP5431495B2 (ja)	2008-12-05	2014-03-05	エフ．ホフマン−ラロシュアーゲー	ピロロピラジニル尿素キナーゼ阻害薬
JOP20190230A1 (ar)	2009-01-15	2017-06-16	Incyte Corp	طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
ES2659725T3 (es)	2009-05-05	2018-03-19	Dana-Farber Cancer Institute, Inc.	Inhibidores de EGFR y procedimiento de tratamiento de trastornos
JO3030B1 (ar)	2009-06-26	2016-09-05	Galapagos Nv	مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
EP2448473A4 (en)	2009-06-30	2014-06-25	Edwards Lifesciences Corp	SYSTEMS AND METHODS FOR MONITORING AND DISPLAYING A PATIENT STATUS
UA110324C2 (en)	2009-07-02	2015-12-25	Genentech Inc	Jak inhibitory compounds based on pyrazolo pyrimidine
JP5690823B2 (ja) *	2009-07-08	2015-03-25	レオファーマアクティーゼルスカブ	Ｊａｋ受容体およびタンパク質チロシンキナーゼ阻害薬としての複素環化合物
US8486355B2 (en)	2009-08-07	2013-07-16	Metaleach Limited	Method for leaching cobalt from oxidised cobalt ores
NZ598985A (en)	2009-09-04	2013-07-26	Biogen Idec Inc	Bruton's tyrosine kinase inhibitors
WO2011072174A1 (en)	2009-12-09	2011-06-16	Agios Pharmaceuticals, Inc.	Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation
UY33213A (es)	2010-02-18	2011-09-30	Almirall Sa	Derivados de pirazol como inhibidores de jak
WO2011144585A1 (en)	2010-05-20	2011-11-24	F. Hoffmann-La Roche Ag	Pyrrolo [2, 3 - b] pyrazine - 7 - carboxamide derivatives and their use as jak and syk inhibitors
TW201204732A (en) *	2010-07-09	2012-02-01	Leo Pharma As	Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
EP2629777B1 (en) *	2010-10-22	2018-12-19	Merck Sharp & Dohme Corp.	Bicyclic diamines as janus kinase inhibitors
EP2788000B1 (en) *	2011-12-06	2018-05-30	Merck Sharp & Dohme Corp.	Pyrrolopyrimidines as janus kinase inhibitors
SI2796460T1 (sl) *	2011-12-21	2018-10-30	Jiangsu Hengrui Medicine Co. Ltd	Pirolni šestčlenski derivat heteroarilnega obroča, postopek priprave zanj in medicinske uporabe le-tega
JP6318156B2 (ja) *	2012-09-06	2018-04-25	プレキシコンインコーポレーテッドＰｌｅｘｘｉｋｏｎＩｎｃ．	キナーゼをモジュレートするための化合物および方法、ならびにその指標
KR20150082613A (ko)	2012-11-16	2015-07-15	머크 샤프 앤드 돔 코포레이션	인간 포스파티딜이노시톨 3-키나제 델타의 퓨린 억제제
JP2016500076A (ja)	2012-11-20	2016-01-07	プリンシピアバイオファーマインコーポレイテッド	Ｊａｋ３阻害剤としてのアザインドール誘導体
CN103896946B (zh) *	2012-12-28	2018-04-03	浙江导明医药科技有限公司	用于预防及治疗多种自身免疫疾病的新化合物
PE20161246A1 (es) *	2013-12-05	2016-11-25	Pfizer	Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinilo
EP3145512B1 (en) *	2014-05-19	2019-07-17	Jiangsu Hengrui Medicine Co., Ltd.	Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors

2014
- 2014-11-20 PE PE2016000723A patent/PE20161246A1/es unknown
- 2014-11-20 ME MEP-2017-275A patent/ME02883B/me unknown
- 2014-11-20 RS RS20210657A patent/RS61897B9/sr unknown
- 2014-11-20 SI SI201431829T patent/SI3318565T1/sl unknown
- 2014-11-20 CU CU2016000077A patent/CU24396B1/es unknown
- 2014-11-20 WO PCT/IB2014/066202 patent/WO2015083028A1/en not_active Ceased
- 2014-11-20 UA UAA201606072A patent/UA117040C2/uk unknown
- 2014-11-20 CR CR20160250A patent/CR20160250A/es unknown
- 2014-11-20 TN TN2016000227A patent/TN2016000227A1/fr unknown
- 2014-11-20 SI SI201430511T patent/SI3077395T1/en unknown
- 2014-11-20 NZ NZ720092A patent/NZ720092A/en unknown
- 2014-11-20 RS RS20180008A patent/RS56728B1/sr unknown
- 2014-11-20 ES ES17200940T patent/ES2871524T3/es active Active
- 2014-11-20 BR BR112016012262-3A patent/BR112016012262B1/pt active IP Right Grant
- 2014-11-20 MX MX2016007156A patent/MX368464B/es active IP Right Grant
- 2014-11-20 GE GEAP201414164A patent/GEP20186840B/en unknown
- 2014-11-20 HU HUE17200940A patent/HUE054560T2/hu unknown
- 2014-11-20 MY MYPI2016702037A patent/MY187446A/en unknown
- 2014-11-20 AU AU2014358792A patent/AU2014358792C1/en active Active
- 2014-11-20 HR HRP20171846TT patent/HRP20171846T1/hr unknown
- 2014-11-20 PT PT148164049T patent/PT3077395T/pt unknown
- 2014-11-20 KR KR1020167017571A patent/KR101930603B1/ko active Active
- 2014-11-20 LT LTEP14816404.9T patent/LT3077395T/lt unknown
- 2014-11-20 MA MA39092A patent/MA39092B1/fr unknown
- 2014-11-20 LT LTEP17200940.9T patent/LT3318565T/lt unknown
- 2014-11-20 MD MDA20160058A patent/MD4649C1/ro active IP Right Grant
- 2014-11-20 ES ES14816404.9T patent/ES2654051T3/es active Active
- 2014-11-20 PL PL14816404T patent/PL3077395T3/pl unknown
- 2014-11-20 EA EA201600373A patent/EA030472B1/ru unknown
- 2014-11-20 JP JP2016536110A patent/JP6192839B2/ja active Active
- 2014-11-20 HU HUE14816404A patent/HUE035264T2/hu unknown
- 2014-11-20 PL PL17200940T patent/PL3318565T3/pl unknown
- 2014-11-20 DK DK14816404.9T patent/DK3077395T3/en active
- 2014-11-20 CN CN201480074974.2A patent/CN106061973B/zh active Active
- 2014-11-20 AP AP2016009269A patent/AP2016009269A0/en unknown
- 2014-11-20 DK DK17200940.9T patent/DK3318565T3/da active
- 2014-11-20 EP EP14816404.9A patent/EP3077395B1/en active Active
- 2014-11-20 EP EP17200940.9A patent/EP3318565B1/en active Active
- 2014-11-20 CA CA2932425A patent/CA2932425C/en active Active
- 2014-11-20 CN CN201710579812.XA patent/CN107417684A/zh active Pending
- 2014-11-20 PT PT172009409T patent/PT3318565T/pt unknown
- 2014-12-03 UY UY0001035861A patent/UY35861A/es not_active Application Discontinuation
- 2014-12-03 US US14/559,294 patent/US9617258B2/en active Active
- 2014-12-04 AR ARP140104517A patent/AR099363A1/es active IP Right Grant
- 2014-12-04 TW TW103142238A patent/TWI548636B/zh active
2015
- 2015-04-23 NO NO15721089A patent/NO3134430T3/no unknown
2016
- 2016-05-20 PH PH12016500938A patent/PH12016500938B1/en unknown
- 2016-05-20 CL CL2016001216A patent/CL2016001216A1/es unknown
- 2016-06-03 DO DO2016000124A patent/DOP2016000124A/es unknown
- 2016-06-03 GT GT201600098A patent/GT201600098A/es unknown
- 2016-06-03 NI NI201600075A patent/NI201600075A/es unknown
- 2016-06-03 SV SV2016005209A patent/SV2016005209A/es unknown
- 2016-06-05 IL IL246038A patent/IL246038B/en active IP Right Grant
2017
- 2017-03-01 US US15/446,500 patent/US11111242B2/en active Active
- 2017-08-08 JP JP2017152997A patent/JP2018008996A/ja active Pending
- 2017-12-18 CY CY20171101325T patent/CY1119778T1/el unknown
2021
- 2021-05-11 CY CY20211100402T patent/CY1124793T1/el unknown
- 2021-05-13 HR HRP20210770TT patent/HRP20210770T1/hr unknown
- 2021-08-04 US US17/393,463 patent/US12077533B2/en active Active
2023
- 2023-10-03 NL NL301245C patent/NL301245I2/nl unknown
- 2023-11-03 FR FR23C1042C patent/FR23C1042I2/fr active Active
- 2023-11-14 HU HUS2300040C patent/HUS2300040I1/hu unknown
- 2023-11-22 FI FIC20230035C patent/FIC20230035I1/fi unknown
- 2023-11-23 LU LU00322C patent/LUC00322I2/fr unknown
- 2023-12-13 LT LTPA2023537C patent/LTC3077395I2/lt unknown
2024
- 2024-01-09 NO NO2024001C patent/NO2024001I1/no unknown
- 2024-02-09 CY CY2024002C patent/CY2024002I2/el unknown
- 2024-07-15 US US18/772,655 patent/US20250134869A1/en active Pending

Also Published As

Publication number	Publication date
BR112016012262B1 (pt)	2021-04-13
JP2016539137A (ja)	2016-12-15
CY2024002I1 (el)	2024-09-20
PT3077395T (pt)	2018-01-03
DK3077395T3 (en)	2018-01-02
NI201600075A (es)	2016-08-09
UY35861A (es)	2015-07-31
MD4649B1 (ro)	2019-09-30
US20170247372A1 (en)	2017-08-31
CR20160250A (es)	2016-09-19
US12077533B2 (en)	2024-09-03
AU2014358792A1 (en)	2016-06-02
LT3318565T (lt)	2021-06-25
RS61897B1 (sr)	2021-06-30
ME02883B (me)	2018-04-20
WO2015083028A1 (en)	2015-06-11
NZ720092A (en)	2019-05-31
TWI548636B (zh)	2016-09-11
NO3134430T3 (lt)	2018-08-18
US20250134869A1 (en)	2025-05-01
HUS2300040I1 (hu)	2023-12-28
EP3318565A1 (en)	2018-05-09
KR20160092012A (ko)	2016-08-03
DOP2016000124A (es)	2016-10-31
DK3318565T3 (da)	2021-05-25
MD4649C1 (ro)	2020-04-30
PL3077395T3 (pl)	2018-04-30
AU2014358792B2 (en)	2017-06-08
RS61897B9 (sr)	2021-09-30
RS56728B1 (sr)	2018-03-30
LUC00322I2 (lt)	2026-02-02
SV2016005209A (es)	2018-04-11
MA39092B1 (fr)	2018-09-28
EA030472B1 (ru)	2018-08-31
HUE054560T2 (hu)	2021-09-28
CY1119778T1 (el)	2018-06-27
BR112016012262A2 (pt)	2020-06-30
CL2016001216A1 (es)	2017-01-20
LTC3077395I2 (lt)	2025-09-10
CY1124793T1 (el)	2022-11-25
FR23C1042I2 (fr)	2024-11-15
SI3077395T1 (en)	2018-03-30
JP6192839B2 (ja)	2017-09-06
PH12016500938A1 (en)	2016-06-27
EP3077395B1 (en)	2017-11-15
GEP20186840B (en)	2018-04-10
EA201600373A1 (ru)	2016-10-31
AU2014358792C1 (en)	2021-08-26
MA39092A1 (fr)	2018-06-29
FIC20230035I1 (fi)	2023-11-22
NO2024001I1 (no)	2024-01-09
CU24396B1 (es)	2019-04-04
ES2871524T3 (es)	2021-10-29
LTPA2023537I1 (lt)	2024-01-10
CN106061973B (zh)	2019-07-09
MX2016007156A (es)	2016-07-21
MX368464B (es)	2019-10-02
HRP20171846T1 (hr)	2018-01-12
PH12016500938B1 (en)	2016-06-27
PT3318565T (pt)	2021-05-28
CN106061973A (zh)	2016-10-26
ES2654051T3 (es)	2018-02-12
HRP20210770T1 (hr)	2021-06-25
CY2024002I2 (el)	2024-09-20
MD20160058A2 (ro)	2016-11-30
IL246038A0 (en)	2016-08-02
CN107417684A (zh)	2017-12-01
PE20161246A1 (es)	2016-11-25
FR23C1042I1 (fr)	2023-12-29
CA2932425A1 (en)	2015-06-11
KR101930603B1 (ko)	2018-12-18
JP2018008996A (ja)	2018-01-18
CA2932425E (en)	2015-06-11
UA117040C2 (uk)	2018-06-11
US20150158864A1 (en)	2015-06-11
US20230009153A1 (en)	2023-01-12
IL246038B (en)	2020-10-29
AR099363A1 (es)	2016-07-20
US11111242B2 (en)	2021-09-07
EP3318565B1 (en)	2021-04-14
GT201600098A (es)	2019-10-17
NL301245I2 (nl)	2023-11-20
CU20160077A7 (es)	2017-01-10
TW201524977A (zh)	2015-07-01
TN2016000227A1 (fr)	2017-10-06
PL3318565T3 (pl)	2021-10-04
US9617258B2 (en)	2017-04-11
HUE035264T2 (hu)	2018-05-02
SI3318565T1 (sl)	2021-07-30
MY187446A (en)	2021-09-22
CA2932425C (en)	2018-07-17
EP3077395A1 (en)	2016-10-12
AP2016009269A0 (en)	2016-06-30

Publication	Publication Date	Title
HUS2300040I1 (hu)	2023-12-28	Pirrolo[2,3-d]pirimidinil-, pirrolo[2,3-b]pirazinil- és pirrolo[2,3-d]-piridinil- akrilamidok
ZA201503828B (en)	2016-09-28	Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
IL246311A0 (en)	2016-08-02	Pyrazolo[5,1-a]pyridine derivatives and methods of using them
ZA201507874B (en)	2017-09-27	2-aminopyrido[4,3-d]pyrimidin-5-one derivatives and their use as wee-1 inhibitors
IL243092B (en)	2019-06-30	New triazolo[d–4,5]pyrimidine histories
IL243525A0 (en)	2016-02-29	Benzyl-1h-pyrazolo[4,3-b]pyridines and their use
EP2970278A4 (en)	2016-12-07	Pyrrolo [2,3] PYRIDINE KINASE INHIBITORS CDK9-
ZA201507151B (en)	2017-01-25	Antiviral indolo[2,3-b]quinoxaline
PT2989105T (pt)	2020-04-22	Compostos de pirazino[1,2-a]indole, sua preparação e utilização em medicamentos
ZA201508613B (en)	2017-08-30	Pyrazino[1,2-a]indole compounds, their preparation and use in medicaments
TH1601003263A (th)	2017-09-21	ไพร์โรโล[2,3-d]ไพริมิดินิล, ไพร์โรโล[2,3-b]ไพราซินิล และ ไพร์โรโล[2,3-d] ไพริดินิล เอคริลเอไมด์